Pacific Biosciences of California (PACB) - Total Liabilities

Latest as of December 2025: $778.73 Million USD

Based on the latest financial reports, Pacific Biosciences of California (PACB) has total liabilities worth $778.73 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PACB operating cash flow to assess how effectively this company generates cash.

Pacific Biosciences of California - Total Liabilities Trend (2008–2025)

This chart illustrates how Pacific Biosciences of California's total liabilities have evolved over time, based on quarterly financial data. Check PACB asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Pacific Biosciences of California Competitors by Total Liabilities

The table below lists competitors of Pacific Biosciences of California ranked by their total liabilities.

Company Country Total Liabilities
Korea Electronic Power Industrial Development Co Ltd
KO:130660
Korea ₩112.70 Billion
Shenmao Technology Inc
TW:3305
Taiwan NT$6.38 Billion
BHG Group AB (publ)
ST:BHG
Sweden Skr4.57 Billion
Doubledown Interactive Co Ltd
NASDAQ:DDI
USA $90.13 Million
Jiangsu Yabang Dyestuff Co Ltd
SHG:603188
China CN¥882.69 Million
Advanced Power Electronics Corp
TW:8261
Taiwan NT$759.45 Million
Lihe Technology
SHE:300800
China CN¥449.77 Million
Yeo Teknoloji Enerji ve Endustri AS
IS:YEOTK
Turkey TL16.00 Billion

Liability Composition Analysis (2008–2025)

This chart breaks down Pacific Biosciences of California's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Pacific Biosciences of California.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 6.89 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 145.58 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.99 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pacific Biosciences of California's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pacific Biosciences of California (2008–2025)

The table below shows the annual total liabilities of Pacific Biosciences of California from 2008 to 2025.

Year Total Liabilities Change
2025-12-31 $778.73 Million +3.30%
2024-12-31 $753.85 Million -27.84%
2023-12-31 $1.04 Billion -13.24%
2022-12-31 $1.20 Billion -0.97%
2021-12-31 $1.22 Billion +1449.24%
2020-12-31 $78.49 Million -15.66%
2019-12-31 $93.07 Million +65.56%
2018-12-31 $56.21 Million -3.05%
2017-12-31 $57.98 Million +8.95%
2016-12-31 $53.22 Million -7.56%
2015-12-31 $57.57 Million -17.26%
2014-12-31 $69.57 Million +3.83%
2013-12-31 $67.00 Million +230.06%
2012-12-31 $20.30 Million -24.40%
2011-12-31 $26.85 Million +3.76%
2010-12-31 $25.88 Million -90.70%
2009-12-31 $278.22 Million +34.73%
2008-12-31 $206.50 Million --

About Pacific Biosciences of California

NASDAQ:PACB USA Medical Devices
Market Cap
$483.20 Million
Market Cap Rank
#13176 Global
#3029 in USA
Share Price
$1.60
Change (1 day)
+0.63%
52-Week Range
$0.91 - $2.67
All Time High
$51.15
About

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more